Search Results

Pharm Country

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.

March 27, 2024

·

7 min read

Business

Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

Daxor Corporation today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer.

June 5, 2024

·

4 min read

Policy

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.

December 1, 2023

·

6 min read

Pharm Country

L2P Research Labs Awarded NIH SBIR Grant for Arthritis, Musculoskeletal and Skin Diseases Research

L2P Research, LLC, a leading preclinical CRO, today announced the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

October 27, 2023

·

1 min read

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

Ono Pharmaceutical Co., Ltd. announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P., which was established as a corporate venture capital fund in CA, USA in May 2020.

December 1, 2023

·

1 min read

Press Releases

David P. King Joins Truvian’s Advisory Board

January 13, 2025

·

2 min read

FDA signage at its headquarters in Maryland

Stomach cancer

FDA Sets Adcomm Meeting to Assess Checkpoint Inhibitors in Stomach Cancer Using PD-L1

The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.

August 23, 2024

·

2 min read

·

Tristan Manalac

Press Releases

RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy

January 8, 2025

·

3 min read

Press Releases

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference